Keeping Cost Out of the Drug Approval Debate

The FDA has a regulatory function, which is probably best kept without looking at the costs of the medicines. The role is probably best for an independent HTA organization, like NICE. In Europe, the role of the EMA and of the HTA organization are 2 separate things, and that model works very well there.